ReviewImmunotherapy
CAR-iNKT cells for cancer therapy: a comprehensive review of engineering, mechanisms, and clinical progress.
Review in Immunotherapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor (CAR)-modified T cells, as a revolutionary cancer immunotherapy, have achieved remarkable success in hematologic malignancies. However, the therapy is hindered by severe toxicity, complex manufacturing, and suboptimal efficacy in solid tumors. Invariant natural killer T (iNKT) cells combine features of T cells and NK cells, bridging innate and adaptive immunity. Beyond direct cytotoxic functions, iNKT cells exert indirect antitumor effects through interactions with other immune cells while also modulating the tumor microenvironment (TME). Their exceptional TME infiltration capacity offers hope for solid tumor treatment. Leveraging their inherent major histocompatibility complex (MHC)-independent cytotoxicity, iNKT cells offer a viable strategy for developing "off-the-shelf" CAR cell products. Consequently, CAR-iNKT cell therapies developed by introducing CAR technology into iNKT cells demonstrate extraordinary potential as a next generation tumor immunotherapy. Despite being established and garnering attention, CAR-iNKT cell therapy remains nascent with numerous obstacles. This review comprehensively discusses CAR-iNKT cell therapy, from the fundamental biology of iNKT cells to the latest advances in engineering and clinical translation, offering new perspectives for its research, development, and application. A comprehensive literature search was conducted using [PubMed, Embase, and Web of Science] for articles published between [January 1900 and March 2026].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.